GAITHERSBURG, Md. (EGMN) – Panelists at a joint Food and Drug Administration advisory committee meeting voted 20-12 with 1 abstention that the diabetes drug rosiglitazone can continue to stay on the market, but they urged the agency to impose new restrictions and warnings on use of the drug.
